IDEXX Laboratories, Inc. vs Suncor Energy Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $517.55 (market cap $40.43B), while Suncor Energy Inc. trades at $72.09 (market cap $82.76B). The key difference: Suncor Energy Inc. is far larger — about 2× IDEXX Laboratories, Inc.'s market cap, and Suncor Energy Inc. pays a 2.39% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Suncor Energy Inc. for 57 Days on average.
| IDXX | SU | |
|---|---|---|
Market Cap | $40.43B | $82.76B |
Volume | 692,164 | 3,832,959 |
Sector | Health | Energy |
52-Week High | $766.68 | $71.87 |
52-Week Low | $504.70 | $38.17 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | $41.32B | $89.29B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Suncor Energy (SU) trades at $68.14, down slightly by 0.12% on the day. The stock exhibits a bullish technical trend, supported by strong fundamentals including a P/E of 13.46 and a net income margin of 14.7%. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Analyst consensus is strongly positive with 23 buy ratings and no sell recommendations. News highlights include asset divestments and a planned CEO transition to Peter Zebedee in 2027.
The outlook for SU is favorable, driven by robust cash flow, aggressive shareholder returns via buybacks and dividends, and a discounted valuation relative to peers. Key risks include commodity price volatility, operational disruptions from weather events, and execution of the leadership transition. The stock's current price near recent highs suggests momentum, but investors should weigh these factors against the strong fundamental backdrop.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →